HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

azelnidipine

structure given in first source
Also Known As:
3-(1-diphenylmethylazetidin-3-yl)-5-isopropyl-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; CS 905; CS-905; 3,5-Pyridinedicarboxylic acid, 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-(1-(diphenylmethyl)-3-azetidinyl) 5-(1-methylethyl) ester, (+-)-
Networked: 101 relevant articles (22 outcomes, 37 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Shimada, Kazuyuki: 6 articles (03/2013 - 06/2007)
2. Daida, Hiroyuki: 5 articles (01/2015 - 10/2009)
3. Sunagawa, Kenji: 5 articles (01/2012 - 09/2006)
4. Miyauchi, Katsumi: 4 articles (01/2015 - 10/2009)
5. Ito, Hiroshi: 4 articles (01/2014 - 10/2009)
6. Kario, Kazuomi: 4 articles (03/2013 - 06/2007)
7. Ogihara, Toshio: 4 articles (05/2010 - 02/2004)
8. Horiuchi, Masatsugu: 4 articles (12/2006 - 02/2004)
9. Inoue, H: 4 articles (11/2006 - 01/2005)
10. Yamagishi, S: 4 articles (11/2006 - 01/2005)

Related Diseases

1. Hypertension (High Blood Pressure)
2. Albuminuria
3. Insulin Resistance
4. Inflammation
01/01/2010 - "We examined whether a new CCB (azelnidipine) could influence the inflammatory response of human peripheral blood mononuclear cells (PBMCs), which are recruited to inflammatory lesions and modulate inflammation. "
12/15/2006 - "These findings imply a protective role of azelnidipine against inflammation in atherosclerosis."
10/01/2014 - "In the present study, we examined the efficacy of olmesartan and azelnidipine monotherapy (2 mg/kg or 10 mg/kg each) and their combination therapy (1 mg/kg each) on stroke-prone spontaneously hypertensive rats (SHR-SP) in relation to oxidative stress, inflammation, and the neurovascular unit. "
11/01/2009 - "It is suggested that the combination of olmesartan and azelnidipine has advantages over the combination of olmesartan and a thiazide with respect to avoiding hyperuricemia, sympathetic activation, renin-angiotensin-aldosterone system stimulation, inflammation, oxidative stress, and increased arterial stiffness in patients with moderate hypertension. "
04/01/2011 - "The adjusted percent reduction in UACR in the olmesartan/HCTZ group was significantly greater than that in the olmesartan/azelnidipine group (-43.2 vs. -24.0%, P = 0.0014), although the olmesartan/azelnidipine group showed greater decreases in central systolic BP (SBP; P = 0.04), oxidative stress (urinary 8-isoprostane; P = 0.02), inflammation (high-sensitivity C-reactive protein; P = 0.04), and insulin resistance (the homeostasis model assessment insulin resistance index (HOMA(IR)); P < 0.001) than the olmesartan/HCTZ group. "
5. Myocardial Stunning (Stunned Myocardium)

Related Drugs and Biologics

1. Amlodipine (Norvasc)
2. olmesartan
3. Calcium Channels (Calcium Channel)
4. 1,4-dihydropyridine (dihydropyridine)
5. olmesartan medoxomil (Votum)
6. Antihypertensive Agents (Antihypertensives)
7. Nifedipine (Adalat)
8. Trichlormethiazide (Naqua)
9. Angiotensin Receptors (Angiotensin II Receptor)
10. zofenopril

Related Therapies and Procedures

1. Stents
2. Transplants (Transplant)
3. Peritoneal Dialysis
4. Microelectrodes
5. Oral Administration